- Home
- TXO vs REPL Comparison
TXO vs REPL Comparison
Compare TXO & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXO
- REPL
- Stock Information
- Founded
- TXO 2012
- REPL 2015
- Country
- TXO United States
- REPL United States
- Employees
- TXO N/A
- REPL N/A
- Industry
- TXO Oil & Gas Production
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- TXO Energy
- REPL Health Care
- Exchange
- TXO Nasdaq
- REPL Nasdaq
- Market Cap
- TXO 739.8M
- REPL 816.4M
- IPO Year
- TXO 2023
- REPL 2018
- Fundamental
- Price
- TXO $18.03
- REPL $11.05
- Analyst Decision
- TXO Strong Buy
- REPL Strong Buy
- Analyst Count
- TXO 2
- REPL 4
- Target Price
- TXO $26.00
- REPL $17.00
- AVG Volume (30 Days)
- TXO 67.7K
- REPL 508.2K
- Earning Date
- TXO 11-05-2024
- REPL 11-12-2024
- Dividend Yield
- TXO 13.29%
- REPL N/A
- EPS Growth
- TXO N/A
- REPL N/A
- EPS
- TXO N/A
- REPL N/A
- Revenue
- TXO $285,451,000.00
- REPL N/A
- Revenue This Year
- TXO N/A
- REPL N/A
- Revenue Next Year
- TXO $31.77
- REPL $469.74
- P/E Ratio
- TXO N/A
- REPL N/A
- Revenue Growth
- TXO N/A
- REPL N/A
- 52 Week Low
- TXO $17.20
- REPL $4.92
- 52 Week High
- TXO $23.56
- REPL $12.97
- Technical
- Relative Strength Index (RSI)
- TXO 39.44
- REPL 45.85
- Support Level
- TXO $17.78
- REPL $10.57
- Resistance Level
- TXO $18.51
- REPL $12.73
- Average True Range (ATR)
- TXO 0.51
- REPL 0.66
- MACD
- TXO -0.07
- REPL -0.14
- Stochastic Oscillator
- TXO 23.24
- REPL 29.58
About TXO TXO Partners L.P. Common Units Representing Limited Partner Interests
TXO Partners LP is focused on the acquisition, development, optimization and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.